Semax Regulatory Status

Educational overview only. Not legal or medical advice. Rules change by country and over time. This page explains the big picture in plain language so visitors can orient themselves. It is not a clearance to import, prescribe, compound, or use Semax.

Intro

For most Semax Hub visitors, the question that matters first is the United States picture: Semax is not a U.S. Food and Drug Administration (FDA)-approved drug, and U.S. pharmacy compounding under section 503A (the federal pathway for patient-specific compounding by state-licensed pharmacies) is in flux after 2026 FDA process steps. Russia is where Semax is a registered prescription nasal medicine. Those are different regulatory worlds. Mixing "approved somewhere" with "legal to compound or sell everywhere" is how confusion starts.

United States

Not an FDA-approved medicine

Semax is not approved by the U.S. Food and Drug Administration for any indication as a marketed drug. There is no FDA-approved Semax product label for routine prescribing the way there is for many branded or generic central nervous system (CNS) medicines. Not FDA-approved does not by itself prove the molecule is "fake." It does mean FDA has not endorsed benefit–risk for routine U.S. clinical marketing under its drug-approval standards.

Semax is also not covered by a United States Pharmacopeia (USP) or National Formulary (NF) drug-substance monograph in the materials FDA has cited for compounding review.

Compounding under section 503A

U.S. state-licensed pharmacies that compound under section 503A of the Federal Food, Drug, and Cosmetic Act generally need a lawful bulk-drug pathway (for example: an FDA-approved drug product, a USP/NF monograph substance, or a substance on FDA's 503A Bulks List after formal listing). Peptides that sit outside those pathways are a common source of gray-market and enforcement confusion.

FDA has also used interim categories while evaluating nominated bulk substances:

Uncertainty flag: Interim category placement is not the same as a final rule adding a substance to the 503A Bulks List at 21 CFR 216.23.

April 2026: off Category 2 (procedural, not a green light)

In mid-April 2026, nominators withdrew Semax nominations for the 503A Bulks List. FDA then removed Semax from the interim Category 2 list (public reporting commonly cites effect around April 22, 2026).

That step is easy to misread. In plain language:

• What it was: a procedural consequence of withdrawn nominations (a withdrawn nomination can't sit in Category 2).
• What it was not: a finding that safety concerns vanished; a move into Category 1; FDA approval; or permission for 503A pharmacies to compound Semax.

FDA separately announced a Pharmacy Compounding Advisory Committee (PCAC) meeting to consider Semax and other peptides for the 503A Bulks List (Federal Register meeting notice dated April 16, 2026).

July 23–24, 2026 PCAC: Bulks List recommendation (not "remove from Category 2")

On July 24, 2026, PCAC discussed Semax-related bulk drug substances: Semax (free base) and Semax acetate. FDA's meeting materials state the uses evaluated included cerebral ischemia, migraine, and trigeminal neuralgia. Nominated product ideas discussed in FDA materials included intranasal spray and, in some nomination materials, subcutaneous injection strengths.

Important split:

1. FDA staff position (briefing materials): FDA proposed that Semax (free base) NOT be included on the 503A Bulks List, and that Semax acetate NOT be included, citing characterization and related quality/safety concerns (including issues discussed in FDA's Semax briefing package such as inconsistent naming / salt vs free-base documentation and potential immunogenicity / impurity risks for certain routes).
2. Committee recommendation (meeting reports): Law-firm and trade press meeting reports state PCAC voted roughly 8–5 (with an abstention in some tallies) to recommend adding Semax free base and Semax acetate to the 503A Bulks List anyway. Treat vote numbers as meeting-report tallies until FDA posts certified minutes / the official vote record.

That July action was about whether to recommend listing on the 503A Bulks List. It was not a vote to "remove Semax from Category 2" (Category 2 removal had already happened in April for procedural reasons).

What still must happen before 503A compounding is clearly on the table

A favorable PCAC recommendation is advice to FDA, not a finished federal permission slip. Before visitors should read the landscape as "U.S. compounding pharmacies can compound Semax under 503A," here's what still needs to happen:

1. FDA decision: FDA may accept, modify, or reject the committee's recommendation. Advisory committee advice is nonbinding.
2. Notice-and-comment rulemaking: Formally adding a bulk substance to the 503A Bulks List typically requires proposed rule → public comment → final rule (and appearance in the operative list / 21 CFR 216.23 as applicable).
3. Clear listing or other clear policy: Until Semax appears on the final Bulks List (or FDA issues another clear, operative policy that actually authorizes the use), the July vote alone should not be treated as authorization.
4. State pharmacy law: Even with a federal pathway, state boards of pharmacy, prescription requirements, and professional practice rules still apply.
5. Still not "FDA-approved Semax": Bulks-list compounding eligibility (if it ever finalizes) is not the same as FDA approval of a Semax drug product for safety and effectiveness.

Bottom line for newcomers: As of September 2026, Semax remains unapproved as a U.S. drug product, and a PCAC recommendation should not be marketed as "now legal to compound everywhere."

Online “research” listings

Many online listings sell Semax-like peptides as research chemicals, not as FDA-approved medicines and not as verified 503A pharmacy preparations. Identity, purity, and legality are separate questions. Semax Hub does not evaluate vendors and does not sell Semax.

Russia

Registered prescription nasal medicine

In the Russian Federation, Semax is authorized as a medicinal product. Public manufacturer materials and prescribing texts cite registration numbers such as:

• ЛС-002553 (dated 30 December 2011): Semax nasal drops 0.1%
• Related registrations also appear in manufacturer materials (e.g. Р N000812/01)

The pharmaceutical group on the label is a nootropic agent (Anatomical Therapeutic Chemical (ATC) code N06BX). Dosage forms discussed in Russian practice are nasal drops, historically including 0.1% and a higher-concentration 1% preparation oriented to heavier cerebrovascular use. Official instructions describe release by prescription.

Russian clinical-practice writing discusses neurology-related uses (for example cerebrovascular cognitive problems, post-stroke recovery settings, optic-nerve protocols). Those are Russian regulatory and practice claims, not FDA-approved indications.

Vital and Essential Drugs list (ЖНВЛП)

Russia maintains a national List of Vital and Essential Drugs (ЖНВЛП). Secondary sources state Semax appears on the list associated with Government Order № 2199-р of 7 December 2011 (list for 2012). That is national essential-medicines policy context. It does not create U.S. or EU approval.

Uncertainty flag: Lists update. Verify current ГРЛС / ЖНВЛП entries when currency matters.

Who developed it

Semax emerged from Russian peptide research associated with the Institute of Molecular Genetics (Russian Academy of Sciences) and collaborators (notably work connected with N.F. Myasoedov and I.P. Ashmarin). Commercial nasal products have been associated with Peptogen in Moscow. Named Russian pharmacy Semax is not the same evidentiary or quality world as anonymous online powders.

Elsewhere

Major Western regulators such as the European Medicines Agency (EMA) have not, in the usual marketing-authorization sense visitors mean, approved Semax as a standard human medicine. Status outside the U.S. and Russia varies by country. This page does not map every customs or pharmacy statute.

Uncertainty flags

1. PCAC vote tallies in press/law-firm reports may precede FDA's certified minutes. Prefer the official record when it posts.
2. Interim Category 1/2/3 tables and safety-risk pages are updated over time. Recheck FDA's current compounding pages when making time-sensitive decisions.
3. "Removed from Category 2" ≠ "added to Category 1" ≠ "on the 503A Bulks List" ≠ "FDA-approved drug."
4. State and federal rules can diverge; this is orientation, not counsel.
5. Semax Hub pages are educational only. Not legal advice. Not medical advice. No dosing. No buy links.

Sources

United States / 2026 compounding pathway

1. FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (meeting page; Semax uses evaluated: cerebral ischemia, migraine, trigeminal neuralgia).
2. FDA. FDA Briefing Document for the July 23–24, 2026 PCAC meeting (Semax-related bulk drug substances; staff propose Semax free base and Semax acetate NOT be included on the 503A Bulks List; notes nominations withdrawn but FDA elected to proceed).
3. FDA. PCAC presentation materials on Semax-related bulk drug substances.
4. Federal Register. Pharmacy Compounding Advisory Committee notice of meeting (published April 16, 2026; document 2026-07361).
5. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Category 1/2/3 update PDF; withdrawn-nomination / category mechanics).
6. FDA. Safety risks associated with certain bulk drug substances nominated for use in compounding (includes discussion of substances previously in Category 2 / withdrawn).
7. Meeting-report tallies for the July 24 Semax vote (use until certified FDA minutes are posted), e.g. McDermott Will & Emery meeting summary; Bass, Berry & Sims; RAPS/Regulatory Focus coverage of the July 23–24, 2026 PCAC peptide votes.

Russia

8. Official Russian prescribing information: Semax nasal drops 0.1%, registration ЛС-002553 (30.12.2011); prescription release; ATC N06BX. Package insert PDF
9. Russian Government Order № 2199-р (7 December 2011) / Vital & Essential Drugs list for 2012: Minzdrav document page
10. Kolomin T, et al. Neuroscience & Medicine. 2013;4:223-252. doi:10.4236/nm.2013.44035